 CAMBRIDGE, Mass.--BUSINESS WIRE--Infinity Pharmaceuticals, Inc. NASDAQ: INFI today announced two poster presentations featuring clinical data from ongoing studies evaluating eganelisib in triple negative breast cancer TNBC at the upcoming San Antonio Breast Cancer Symposium SABCS being held virtually, December 8-11, 2020. Presentation Details: Title: MARIO-3 phase II study initial data evaluating a novel triplet combination of eganelisib IPI-549, atezolizumab atezo, and nab-paclitax 